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Abstract
Background
Candida is an important cause of bloodstream infections (BSI) in nosocomial settings caus-
ing significant mortality and morbidity. This study was performed to evaluate contemporary
epidemiology, species distribution, antifungal susceptibility and outcome of candida BSI in
an Italian hospital.
Methods
All consecutive patients who developed candidemia at Santa Maria della Misericordia Uni-
versity Hospital (Italy) between January 2009 and June 2014 were enrolled in the study.
Results
A total of 204 episodes of candidemia were identified during the study period with an inci-
dence of 0.79 episodes/1000 admissions. C. albicans was isolated in 60.3% of cases, fol-
lowed by C. parapsilosis (16.7%), C. glabrata (11.8%) and C. tropicalis (6.4%). Of all
Candida BSI, 124 (60.8 %) occurred in patients admitted to IMW, 31/204 (15.2 %) in ICUs,
33/204 (16.2%) in surgical units and 16/204 (7.8%) in Hematology/Oncology wards. Over-
all, 47% of patients died within 30 days from the onset of candidemia. C. parapsilosis and C.
glabrata candidemia were associated with the lowest mortality rate (36%), while patients
with C. tropicalis BSI had the highest mortality rate (58.3%). Lower mortality rates were de-
tected in patients receiving therapy within 48 hours from the time of execution of the blood
cultures (57,1% vs 38,9%, P <0.05). At multivariate analysis, steroids treatment (OR= 0.27,
p=0.005) and CVC removal (OR=3.77, p=0.014) were independently associated with lower
and higher survival probability, respectively. Candidemia in patients with peripherally in-
serted central catheters (PICC) showed to be associated with higher mortality in compari-
son with central venous catheters (CVC, Short catheters and Portacath) and no CVC use.
For each point increase of APACHE III score, survival probability decreased of 2%.
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Caspofungin (OR=3.45, p=0.015) and Amphothericin B lipid formulation (OR=15.26,
p=0.033) were independently associated with higher survival probability compared with
no treatment.
Introduction
Candida spp. is currently the main protagonist of fungal infections in hospitalized patients, rep-
resenting the fourth and sixth leading cause of nosocomial sepsis in European and US studies,
respectively [1,2]. A recent American study reported Candida as the first cause of bloodstream
infections (BSI) in 180 medical centres [3]. Data are available from large series of laboratory-
based [4] and population-based [5] surveillance studies, as well as studies focusing on specific
patient populations such as neonates [6,7], cancer [8,9], surgical [10,11] and critically ill patients
[12,13]. According to the data reported by the European Centre for Disease prevention and Con-
trol (ECDC) in 2013, Candida spp. is actually the fifth microorganism responsible of causing
sepsis in patients admitted to the ICU. Recently, an increase in incidence has been related to the
complex medical and surgical procedures undertaken to prolong the survival of critically ill pa-
tients and the change in the demographic characteristics of hospitalized populations [14,15].
The epidemiology of candidemia varies according to geographical regions [16,17]. For this
reason, continuous surveillance studies to monitoring incidence, species distribution, and anti-
fungal susceptibility profiles are mandatory.
Candidemia remains associated with high crude and attributable mortality rates along with-
increased cost of care and duration of hospitalization [18]. Attributable mortality has been re-
ported to range from 5% to 71% [13,19], and crude mortality rates can be as high as 76% [20].
The increase of the attributable mortality of candidemia has driven research into the role of
early diagnosis and prompt treatment initiation in order to improve outcomes [21,22]. Inade-
quate initial antifungal treatment has been associated with increased mortality in patients with
candidemia [23]. Furthermore, intrinsic and emerging resistance to azoles represents a major
challenge for empirical therapeutic and prophylactic strategies [24,25].
This study was performed to evaluate contemporary epidemiology, species distribution, an-
tifungal susceptibly and outcome of candida BSI in an Italian hospital.
Methods
This study was approved by the local institutional review board (Comitato Etico Unico
Azienda Ospedaliera Universitaria Santa Maria della Misericordia) and written patient consent
was not required because of the observational nature of this study. Patient characteristics were
collected from an electronic database where records and information were anonymized and
de-identified prior to analysis.
This is a retrospective, single-centre, observational cohort study conducted at Santa Maria
della Misericordia hospital (Udine, Italy), a tertiary University Hospital with 960 beds and
44,000 admissions per year. All patients who developed candidemia, defined as patients with at
least a positive blood culture for Candida spp. and a compatible clinical illness during the period
January 2009—June 2014 were included in the study. Only the first episode of candidemia was
recorded for each patient. Patients with “mixed candidemia”, identified as the isolation of two
different Candida species from blood cultures performed on the same day or at a distance of at
least 7 days, were also included. Clinical data were collected from the microbiological laboratory
database and included underlying diseases, risk factors for candida infection (neutropenia,
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intravascular-devices, the administration of total parental nutrition, prior antimicrobial admin-
istration, prior antifungal therapy, recent abdominal/extra-abdominal surgery, major (surgery
involving a risk to the life of the patient) and minor (an operation on the superficial structures
of the body or a manipulative procedure that does not involve a serious risk) surgery, chemo-
therapy, radiation treatment, recent ICU admission, immunosuppressive treatment, bone mar-
row or solid-organ transplant), Candida species and susceptibility to antifungal agents, timing
of antifungal administration (determined as the interval between the time when the first Candi-
da-positive blood sample for culture was drawn and the time when the antifungal treatment
was first administered to the patient) and outcome. Initial treatment was considered adequate
when the infecting organism was ultimately shown to be susceptible and the dosage of antifun-
gal used was adequate within the first 24 hours from culture positivity. The following antifungal
dosages were considered adequate: fluconazole 800 mg loading dose followed by a daily dosage
of at least 400 mg, liposomal amphotericin B (L-AmB) 3 mg/kg/day, amphotericin lipid com-
plex (ABLC) 5mg/kg/day, caspofungin 70 mg loading dose followed by 50 mg/day, micafungin
100 mg/day, anidulafungin 200 mg loading dose followed by 100 mg/day.
Crude mortality rate was calculated at 30 days from blood cultures performing. No changes
in the microbiological laboratory techniques at our hospital were undertaken during the study
period. Candida spp. was isolated from blood samples using the Bactec 860 system (Becton,
Dickinson, Inc., Sparks, MD). The species were identified using the API ID 32C system (bio-
Mérieux, Marcy l'Etoile, France) or the Vitek 2 system (bioMérieux). In the cases of inconclu-
sive results obtained by both systems, isolates were definitively identified using supplemental
tests, e.g., by the presence or absence of well-formed pseudohyphae on cornmeal-Tween 80
agar and growth at 42 to 45°C. C. parapislosis strains were identified only at complex level.
Susceptibility to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole
was detected using the Sensititre YeastOne colorimetric plate (Trek Diagnostic Systems, Cleve-
land, OH). Until October 2011 MIC values were interpreted according to species-specific clini-
cal breakpoints as established by the Clinical and Laboratory Standards Institute (CLSI) for
amphotericin B, caspofungin, fluconazole, itraconazole (only for C. albicans), and voriconazole
[26]. From November 2011 MIC values were interpreted according to species-specific clinical
breakpoints as established by European Committee on Antimicrobial Susceptibility Testing
(EUCAST) [27,28], updated to the last version available.
Continuous and categorical data were reported as median, 25° and 75° percentile and fre-
quency distributions, respectively. The Wilcoxon test and χ2 test were used to determine if dif-
ferences existed between groups for continuous and categorical variables, respectively. Multiple
logistic regression analysis was performed to identify risk factors that were associated with hos-
pital mortality at 3 months (JMP, SAS, NC, USA). Covariates that were significant at 0.10 in
the univariate analysis were further evaluated for inclusion in multivariable regression models,
using a stepwise algorithm. All tests were 2-tailed, and a p-value<0.05 was determined to rep-
resent statistical significance.
Results
A total of 204 episodes of candidemia, corresponding to an incidence of 0.79 cases / 1000 admis-
sions, was recorded during the study period. The incidence of candidemia corresponded to 0.70–
0.84–0.77–0.93–0.72 episodes /1000 admissions for 2009, 2010, 2011, 2012, and 2013, respective-
ly. The demographic and clinical characteristics of the patients are summarized in Table 1. The
most frequently represented age group was 61 to 80 years of age (46.9% of cases): more than 73%
of candidemia were recorded in patients older than 60 years. During the study period, the mean
age of the population rose from 61.2 years in 2009 to 73.5 years in 2014. Over 87% of the patients
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(178/204) had one or more comorbidities at the time of the diagnosis of candidemia. Specifically,
34.8% presented a solid organ malignancy, 27.9% were diabetics, 12.3% presented liver diseases,
8.3% renal failure, and 4.9% a haematological disease. Among immunosuppressive conditions,
55 (26.9%) received steroid therapy, 28 (13.2%) underwent chemo and / or radiotherapy, 7
(2.9%) received monoclonal antibodies and 9 (3.9%) received other immunosuppressive agents.
Seventy patients (34.3%) underwent surgery in the two months prior to candidemia; of these, 31
had undergone major surgery, 18 a minor surgical procedures, and 21 had extra—abdominal op-
erations. Nineteen/70 (24.3%) had a re-intervention in the two months preceding the diagnosis
of candidemia. Forty-nine (24%), were hospitalized in the ICU in the month prior to the diagno-
sis of candidemia. A total of 140 (69.1%) patients received parental nutrition. An intravascular
device was present in 84.4% of the patients on the candidemia was diagnosed. Ninety-one per-
cent of the patients with candidemia had received at least one antibiotic for 7 days during the
month before candidemia diagnosis. An episode of concomitant bacteraemia was detected in
18.8% of patients; of these, 72% was caused by Gram-positive bacteria, 25% by Gram-negative
bacteria and by mixed bacterial flora in the remaining cases.
One hundred and twenty-four cases (60.8%) occurred in patients admitted to IMW, 31/204
(15.2%) in ICUs, 33/204(16.2%) in surgical units, and 16/204 (7.8%) in Hematology/Oncology
wards. Candidemia distribution by hospital ward is shown in Fig 1.
Overall, C. albicans (CA) was the most common pathogen, accounting for 60% of total
cases, followed by C. parapsilosis (17%), C. glabrata (12%), C. tropicalis (6%) and others (5%).
Table 1. Patients’ features and ward distribution among candida species (n = 204).
Candida species
C. albicans
(n = 123)
C. parapsilosis
(n = 34)
C. glabrata
(n = 24)
C. tropicalis
(n = 13)
Others
(n = 10)
All
(n = 204)
60.2% 16.7% 11.8% 6.4% 5.2% 100%
Patients characteristics
Male sex, n (%) 74 (60) 20 (59) 15 (63) 7 (54) 7 (70) 118 (58)
Mean age (SD) 67 (±21) 71 (±18) 71 (±22) 68 (±16) 53 (±18) 67(±20)
Risk factors
Recent ICU admission 31 (25.2) 6 (17.6) 8 (33.3) 0 4 (40) 49 (24)
Central venous catheter (CVC) 105 (85.4) 30 (88.2) 17 (70.8) 11 (84.6) 9 (90) 172 (84.4)
Parenteral nutrition 87 (70.7) 27(79.4) 13 (54.2) 8 (66.7) 6 (60) 141 (69.1)
Antibiotic treatment in the previous
30 days
117 (95.1) 25 (73.5) 23 (95.8) 12 (92.3) 9 (90) 186 (91.2)
Major abdominal surgery 24 (19.5) 5 (14.7) 2 (8.3) 1 (7.7) 1(10) 31 (16.2)
Minor abdominal surgery 11 (8.9) 1 (2.9) 4 (16.7) 2 (11) 0 18 (8.8)
Extra-abdominal surgery 15 (12.2) 3 (8.8) 1(4.2) 2 (20) 0 21 (10.3)
Solid tumor 40 (32.5) 11 (32.3) 10 (41.7) 6 (8) 4 (40) 71 (34.8)
Haematological malignancies 5 (4,1) 1 (2,9) 0 3 (30) 1 (10) 10 (4.9)
Chemo/radio-therapy 13 (10.6) 5 (14.7) 1 (4.2) 5(19) 3 (30) 27 (13.2)
Diabetes mellitus 34 (27.6) 8 (23.5) 8 (33.3) 3 (5) 4 (40) 57 (27.9)
Haemodialysis 14 (11.4) 2 (5.9) 1(4.2) 0 1 (10) 18 (8.8)
Steroid treatment 30 (24,4) 10 (29.4) 8 (33.3) 4 (7) 3 (30) 55 (26.9)
Hospital Units
Medical Units 70 (56.9) 23 (67.6) 15 (62.5) 7 (53.8) 6 (60) 121 (59.3)
Surgical Units 25 (20.3) 2 (5.9) 4 (16.7) 1 (7.7) 1 (10) 33 (16.2)
Hematology/Oncology 5 (4) 4 (11.8) 1 (4.2) 5 (38.5) 2 (20) 17 (8.3)
ICU 23 (18.7) 5 (14.7) 4 (16.7) 0 1 (10) 33 (16.2)
doi:10.1371/journal.pone.0127534.t001
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The proportion of CA versus non-albicans Candida (CAN) changed over the years: CA was re-
sponsible for 66.7% of candidemia in 2009, 67.7% in 2010, 61.7% in 2011, 43.2% in 2012,
61.7% in 2013, and 68.4% in 2014.
Table 2 shows the results of the in vitro activity of 3 systemically active antifungal agents
tested against BSI isolates of Candida spp. based on CLSI and EUCAST breakpoints. The rate
of susceptibility to fluconazole was 98.4% and 99.2% for C. albicans according to CLSI and
EUCAST breakpoints respectively, and 88.2% for C. parapsilosis according to CLSI break-
points. Decreased susceptibility to fluconazole was mostly seen with C. glabrata (83.3%).
Type of treatment and outcome data were available for 190 patients. A total of 108 (56.8%)
patients received adequate antifungal treatment within 48 hours after collection of blood cul-
tures. Ninety patients (47.4%) died within 30 days following the diagnosis of candidemia.
When 30-day mortality was compared among different wards, significantly higher rates
were observed in IMW compared to surgical wards (P = 0.002) and to all the other wards
(P = 0.009). Thirty-day mortality rates for the population that received antifungal therapy
within 48 hours from collection of blood cultures was 38.9% compared to 57.1% observed in
the population in which the timing was> 48 hours (P = 0.03).
Empirical antifungal treatment was different in patients younger and older than 65 years
(p = 0,001) (Table 3). A higher proportion of younger patients received caspofungin treatment
compared to older patients [21/71 (29.6%) vs. 23/103 (17.3%) respectively, P = 0.001].
Table 4 summarizes the significant differences between patients with candidemia who died
within 3 months from the diagnosis of candidemia compared with survivors at univariate
Fig 1. Candida spp. distribution expressed as percentage of total candida species in various hospital wards.
doi:10.1371/journal.pone.0127534.g001
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analysis. Patients who died were significantly older than survivors (73 vs. 67.5 years,
P = 0.005). Compared to patients who died, the survivors had significant lower APACHE III
scores (median 37 vs. 41, p = 0.003). At univariate analysis, abdominal surgery (p<0,001), re-
operation (p = 0,014) and CVC removal (p<0,001) were more frequent in survivors, while ste-
roids treatment was more often present in patients who died (p = 0.006). Distribution of CVC
was significantly different in patients with different mortality outcomes (p = 0.002): in particu-
lar, peripherally inserted central catheters (PICC) use was more frequently used in patients
who died compared to survivors (25,8% vs. 4%
The final logistic regression model included CVC type, steroids treatment, Apache III score,
CVC removal and definitive treatment. Steroids treatment (OR = 0.27, p = 0.005) and CVC re-
moval (OR = 3.77, p = 0.014) were independently associated with lower and higher survival prob-
ability, respectively (Table 5). PICC showed to be associated with higher mortality in comparison
with more used CVCs (Short catheter, Portacath) and no CVC use. Fo each point increase of
APACHE III score there was a 2% decrease of survival probability. Caspofungin (OR = 3.45,
p = 0.015) and Amphothericin B lipid formulation (OR = 15.26, p = 0.033) were independently
associated with significantly higher survival probability in comparison with no treatment.
Discussion
An increased incidence of candidemia in nosocomial settings has been shown by many studies in
the last fifteen years [1,29]. Our study shows a substantial stability in the incidence over the past
5 years. Candidemia was more frequently diagnosed among patients aged 61 to 80 years, with a
progressive increase of the mean age over time. We also observed a progressive, gradual rise of
the population mean age, with an overall increase of more than 10 years during the 5 years of
Table 2. MIC50, MIC90, and susceptibility of Candida strains to antifungals.
Candida species N° (% isolates) Antifungal agent MIC range (μg/mL) MIC 50 (μg/ml) MIC 90 (μg/ml) N° (%) of resistant
or SDD isolates
CLSI EUCAST
C. albicans 123 (60.3%) Fluconazole 0.12–256 0,25 1 2 (1.6) 1 (0.8)
Caspofungin 0.008–1 0,06 0,06 0 N/A
Amphotericin B 0.25–1 0,125 0,5 N/A 0
C. parapsilosis 34 (16.7%) Fluconazole 0.25–256 1 4 1 (2.9) 3 (8.8)
Caspofungin 0.03–2 0.5 0.5 2 (5.9) NR
Amphotericin B 0.016–0.5 0.06 0.25 N/A 0
C. glabrata 24 (11.8%) Fluconazole 1–32 8 16 0 4 (16.7)
Caspofungin Amphotericin B 0.06–0.5 0.06–1 0.12 0.125 0.125 0.5 0 N/A N/A 0
Amphotericin B 0.06–1 0.125 0.5 N/A 0
C.tropicalis 13 (6.4%) Fluconazole 0.5–4 1 4 1(7.7) 1(7.7)
Caspofungin 0.03–0.25 0.06 0,125 0 Na
Amphotericin B 0.12–0.5 0.25 0.5 N/A 0
Others 10 (5%) Fluconazole 0.12–32 1 32 2 (20) 1(10)
Caspofungin 0.12–05 0.25 0.25 0 N/A
Amphotericin B 0,015–0,25 0,06 0,25 N/A 0
All Candida spp. 204 Fluconazole 0.12–256 0.5 8 7 (3.4) 10 (4.9)
Caspofungin 0.008–2 0.06 0.5 0 N/A
Amphotericin B 0.015–1 0.125 0.5 0 0
N/A: breakpoint not available, NR: not recommended
doi:10.1371/journal.pone.0127534.t002
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Table 3. Comparison of clinical characteristics between patients under and over 65 years old.
Under 65 N° (%) (n. = 71) Over 65 N° (%) (n. = 133) p-value
Gender male 45 (63.4) 78 (58.7) 0.433
Median age (range) 53 (37–60) 78 (71–84.5) <0.001
Hospital wards
Internal medicine Wars 39 (54.9) 85 (63.9) NS
Surgical Wards 14 (19.7) 19 (14.3) NS
Intensive Care Units 13 (18.3) 5 (7) 18 (13.5) 11 (8.3) NS
Onco/hematological Units 5 (7) 11 (8.3) NS
CVC
No CVC 5 (7) 27 (20.3) <0.001
Short catheter 36 (50.7) 49 (36.8) <0.001
Umbilical arterial catheter 5 (7) 0 NS
Midline 3 (4.2) 13 (9.8) NS
Peripherally Inserted Central Catheter (PICC) 9 (12.7) 27 (20.3) <0.001
Portacath 13 (18.3) 17 (12.8) <0.001
Total Parenteral Nutrition 51 (71.8) 89 (66.9) 0.471
Percutaneous Enteral Nutrition 4 (5.6) 12 (9) 0.735
Antibiotic treatment 64 (90.1) 121 (91) 0.845
Abdominal surgery 9 (12.7) 23 (17.3) 0.57
Extra-abdominal surgery 10 (14.1) 11 (8.3) 0.193
Reoperation 10 (14.1) 9 (6.8) 0.087
Solid cancer 28 (39.4) 43 (32.3) 0.31
Hematological cancer 6 (8.5) 4 (3) 0.086
Chemo/radiotherapy* 20 (28.2) 8 (6) <0.001
Monoclonal antibodies 5 (7) 2 (1.5) 0.038
Diabetes 24 (33.8) 33 (24.8) 0.172
Liver disease 14 (19.7) 13 (9.8) 0.046
Hemodialysis 8 (11.3) 10 (7.5) 0.368
Steroids 24 (33.8) 31 (23.3) 0.108
Other immunosuppressant therapy 6 (8.5) 3 (2.39 0.04
Mechanical ventilation 20 (28.2) 11 (8.3) <0.001
Apache III 36 (24.5–56.5) 39 (35–52.75) 0.12
Vasopressor use 15 (21.1) 12 (9) 0.015
HIV 4 (5.6) 0 0.006
CVC removal within 24h 11 (15.5) 21 (15.8) 0.956
Empiric antifungal treatment 66 (93) 102 (76.7) 0.001
Empirical treatment
Fluconazole 37 (52.1) 73(54.9) NS
Voriconazole 2(2.8) 0 NS
Amphotericin B lipid-formulations 2 (2.8) 1 (1.5) NS
Caspofungin 21 (29.6) 23 (17.3) 0.001
Other echinocandins 3 (2) 4 (3) NS
Empiric antifungal treatment 66 (93) 102 (76.7) 0.001
Definitive treatment
Fluconazole 9(12.7) 10 (7.5) NS
Voriconazole 2(2.8) 2 (1.5) NS
Amphotericin B lipid-formulations 5 (7) 1 (0.8) NS
Caspofungin 11 (15.5) 18 (13.5) NS
(Continued)
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observation. The increase in mean age partially differs from other studies where a mean age 60
years was reported with no significant changes in the last decade [12,30]. However, our age popu-
lation data aligns perfectly with other Italian studies [16,19,31,32]. As previously reported, our
data suggests that the increase in the incidence of candidemia is related not only to an increased
number of immunocompromised patients, but also to the aging of the population [31].
C. glabrata and C. parapsilosis BSI were more likely to occur in older patients. Conversely,
candidemia caused by less common species, such as C. krusei and C. famata, were more often
associated with younger age. We reported similar or higher proportions of immunocompro-
mised patients compared with other studies [4,12,25]. Furthermore, high proportions of pa-
tients received broad spectrum antibiotics and steroid therapy prior to hospitalization with
candidemia. As previously reported, we also observed high percentages of patients with paren-
teral nutrition and central vascular access, especially in C. parapsilosis fungemia [33]. As con-
firmed by our study, the incidence of candidemia in IMW is increasing [31,34] due to the
increase in the mean age of hospitalized patients, a more extensive use of antibiotics, steroid
therapy, and invasive procedures performed outside the ICUs [34].
Although there is an increasing evidence of the progressive rise of NCA, C. albicans still rep-
resents the most isolated species in Europe [19,35–37]. Although C. albicans was the main iso-
late in our hospital, the distribution varied considerably according to the ward. Similarly to
other studies, C. albicans was the prevalent species in surgical wards, but not in haematology/
oncology where CNA were prevalent [32]. The high proportion of C.albicans BSI observed in
surgical units diverges from what shown by previous studies [2,32]. This could be related to a
limited use of fluconazole prophylaxis performed in these units as previously reported [36].
Among CNA, C. parapsilosis was mostly isolated in IMW where an extensive use of intravascu-
lar-devices is widely practiced and C. krusei was more common among patients with hemato-
logic disorders [38] who frequently receive azole-based prophylaxis or treatment.
Non-susceptibility to fluconazole (8.3%) was slightly higher than the one reported by Euro-
pean (6.3%) and North American (6.6%) studies, but appeared lower compared to other Italian
studies where resistances up to 25% have been documented [16,34].
The presence of a concomitant bacteraemia in around 20% of cases was lower than the one
reported in another study [39].
We showed 30-day mortality rates of 47.4%, similar to the ones reported by a recent study
conducted in 5 Italian and Spanish academic hospitals [18]. During the study period, we did
not observe substantial changes in both source control (e.g., intravascular device removal) and
timing for antifungal treatment initiation, thus suggesting that the management of candidemia
at our institution can still be improved. Antifungal therapy timing is crucial and is known to
significantly impact the mortality of patients with candidemia [18,21,22]. We observed a
Table 3. (Continued)
Under 65 N° (%) (n. = 71) Over 65 N° (%) (n. = 133) p-value
Other echinocandins 2 (2.8) 2 (1.5) NS
Timing of therapy
Within 24h 20 (28.2) 37 (27.8) 0.96
Between 24 and 48h 9 (12.7) 16 (12) 0.893
More than 48 H 2 (2.8) 7 (5.3) 0.418
30-day mortality 30 (42.2) 74 (55.6) 0.071
CVC: central venous catheter
doi:10.1371/journal.pone.0127534.t003
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Table 4. Characteristics of survivors (N = 76) compared with patients with candidemia who died (N = 128).
Alive N° (%) (n. = 76) Deaths N° (%) (n. = 128) p-value
Gender (male) 32 (42.1) 49 (38.3) 0.589
Avarage age (range) 67.5 (53–78) 73 (61.25–83) 0.005
Over 65 years 44 (57.9) 89 (69.5) 0.091
Hospital wards
Internal medicine Wars 39 (51.3) 85 (66.4) NS
Surgical Wards 17 (22.4) 16 (12.5) NS
Intensive Care Units 13 (17.1) 18 (14.1) NS
Onco/hematological Units 7 (9.2) 9 (7) NS
CVC
No CVC 13 (17.1) 19 (14.8) NS
Short catheter 42 (55.3) 43 (33.6) 0.002
Umbilical arterial catheteR 2 (2.6) 3 (2.3) NS
Midline 4 (5.3) 12 (9.4) NS
Peripherally Inserted Central Catheter 3 (4) 33 (25.8) 0.002
Portacath 12 (15.8) 18 (14.1) NS
Total Parenteral Nutrition 49 (64.5) 91 (71.1) 0.324
Percutaneous Enteral Nutrition 7 (9.2) 9 (7) 0.575
Antibiotic treatment 69 (90.8) 116 (90.6) 0.969
Abdominal surgery 21 (27.6) 11 (8.6) <0.001
Extra-abdominal surgery 6 (7.9) 15 (11.7) 0.385
Re-operation 12 (15.8) 7 (5.5) 0.014
Solid cancer 27 (35.5) 44 (34.4) 0.867
Hematological cancer 6 (7.9) 4 (3.1) 0.127
Chemo/radiotherapy* 8 (10.5) 20 (15.6) 0.21
Monoclonal antibodies 2 (2.6) 5 (3.9) 0.629
Diabetes 16 (21.1) 41 (32) 0.091
Liver disease 9 (11.8) 18 (14.1) 0.651
Hemodialysis 10 (13.2) 8 (6.3) 0.093
Steroids 12 (15.8) 43 (33.6) 0.006
Other immunosuppressant therapy 4 (5.3) 5 (3.9) 0.648
Mechanical ventilation 11 (14.5) 20 (15.6) 0.824
Apache III 37 (25.25–44.75) 41 (33–56) 0.003
Vasopressor use 7 (9.2) 20 (15.6) 0.191
HIV 2 (2.6) 2 (1.6) 0.59
Bacteremia 14 (18.4) 24 (18.8) 0.953
CVC removal in 24h 21 (27.6) 11 (8.6) <0.001
Empirical treatment
No treatment 7 (9.2) 9 (22.7) 0.075
Fluconazole 44 (57.9) 29 (22.7) NS
Voriconazole 1 (1.3) 1 (0.8) NS
Caspofungin 18 (23.7) 26 (20.3) NS
Other echinocandins 3 (4) 4 (3.1) NS
Amphotericin B lipid formulation 3 (4) 1 (0.8) NS
Definitive treatment
No treatment 42 (55.3) 100 (78.1) 0.029
Fluconazole 10 (13.2) 9 (7) NS
Caspofungin 16 (21.1) 13 (10.2) 0.029
(Continued)
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significant difference in mortality between the patients who received antifungal therapy within
48 hours of collection of a blood culture and those who were treated after 48 hours. In particu-
lar, medical wards had the lowest rates of timely initiation of antifungal therapy and presented
a significantly higher mortality if compared to surgical wards (P = 0.002).
Our study supports the importance of the source control (e.g., catheter removal) in patients
with candidemia. Source control has previously been shown to be an important determinant of
outcome for patients with serious infections attributed to Candida species [40]. Although con-
troversy exists regarding the need to remove all central venous catheters in candidemic pa-
tients, the recent European guidelines support the early catheter removal [41].
Our results align with a recent patient-level review of candidemia trial that reported im-
proved clinical outcomes in patients receiving an echinocandin [42].
In conclusion, this study confirms that candidemia is an important cause of morbidity and
mortality, especially among elderly patients admitted to IMW. Early identification of risk fac-
tors associated with this disease is necessary to reduce its incidence, and a timely management
is crucial to improve the outcome.
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